Correction & Withdrawal Policies
Article Processing Charges (APC)
Clinical Trials and Reporting guidelines
[1] Zhang, S., Lin, H., Kong, S., Wang, S., Wang, H., Wang, H., Armant, D.R., 2013. Physiological and molecular determinants of embryo implantation. Mol Aspects Med. 34, 939-980.
[2] Macintyre, G., Goranova, T.E., De Silva, D., Ennis, D., Piskorz, A.M., Eldridge, M., Sie, D., Lewsley, L.A., Hanif, A., Wilson, C., et al., 2018. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 50, 1262-1270.
[3] Ridolfi, L., Petrini, M., Fiammenghi, L., Riccobon, A., Ridolfi, R., 2009. Human embryo immune escape mechanisms rediscovered by the tumor. Immunobiology. 214, 61-76.
[4] Ander, S.E., Diamond, M.S., Coyne, C.B., 2019. Immune responses at the maternal-fetal interface. Sci Immunol. 4.
[5] Ashkar, A.A., Di Santo, J.P., Croy, B.A., 2000. Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med. 192, 259-270.
[6] Saito, S., Nakashima, A., Shima, T., Ito, M., 2010. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 63, 601-610.
[7] Nancy, P., Tagliani, E., Tay, C.S., Asp, P., Levy, D.E., Erlebacher, A., 2012. Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. Science. 336, 1317-1321.
[8] Collins, M.K., Tay, C.S., Erlebacher, A., 2009. Dendritic cell entrapment within the pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice. J Clin Invest. 119, 2062-2073.
[9] James-Allan, L.B., Buckley, R.J., Whitley, G.S., Cartwright, J.E., 2020. The phenotype of decidual CD56+ lymphocytes is influenced by secreted factors from decidual stromal cells but not macrophages in the first trimester of pregnancy. J Reprod Immunol. 138, 103082.
[10] Robertson, S.A., Care, A.S., Moldenhauer, L.M., 2018. Regulatory T cells in embryo implantation and the immune response to pregnancy. J Clin Invest. 128, 4224-4235.